請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25735
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳玉怜 | |
dc.contributor.author | I-I Guang | en |
dc.contributor.author | 管奕奕 | zh_TW |
dc.date.accessioned | 2021-06-08T06:27:19Z | - |
dc.date.copyright | 2006-08-03 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-27 | |
dc.identifier.citation | Baylis C. Effects of administered thromboxanes on the intact, normal rat
kidney. Ren Physiol. 1987;10:110-121. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardio. 2005;l39:443-452 Chad J, Galis Z. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol. 2004;24:54-60. Chen YL, Hu CS, Lin FY, Chen YH, Sheu LM, Ku HH, Shiao MS, Chen JW, Lin SJ. Salvianolic acid B attenuates cyclooxygenase-2 expression in vitro in LPS-treated human aortic smooth muscle cells and in vivo in the apolipoprotein-E-deficient mouse aorta. J Cell Biochem. 2006;98:618-631. Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res. 2002;91:845-851. Christen, T., Verin, V., Bochaton-Piallat, M., Popowski, Y., Ramaekers, F., Debruyne, P., Camenzind, E., van Eys, G. & Gabbiani, G. Mechanisms of neointima formation and remodeling in the porcine coronary artery. Circulation. 2001;103:882–888. Chung AW, Rauniyar P, Luo H, Hsiang YN, van Breemen C, Okon EB. Pressure distention compared with pharmacologic relaxation in vein grafting upregulates matrix metalloproteinase-2 and -9. J Vasc Surg. 2005;42:747-756. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De CD, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability. Circulation. 2001;104:921-927. Cipollone F, Fazia M, Iezzi A, Pini B, Cuccurullo C, Zucchelli M, de Cesare D, Ucchino S, Spigonardo F, De Luca M, Muraro R, Bei R, Bucci M, Cuccurullo F, Mezzetti A. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation. 2004;109:1482-1488. Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol. 2004;24:246-255. Defreyn G, Machin SJ, Carreras LO, Dauden MV, Chamone DAF, Vermylen J. Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: reorientation of cyclic endoperoxide metabolism. Br J Haematol. 1981;49:29-41 Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J. 1998 ;12:1063-1073 Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002;8:1249-1256. Faxon DP, Sanborn TA, Haudenschild CC. Mechanism of angioplasty and its relation to restenosis. Am J Cardiol. 1987;60:5B-9B. Filep JG, Fournier A, Foldes-Filep E. Endothelin-1-induced myocardial ischaemia and oedema in the rat: involvement of the ETA receptor, platelet-activating factor and thromboxane A2. Br J Pharmacol. 1994;112:963-971. Fujino T, Yuhki K, Yamada T, Hara A, Takahata O, Okada Y, Xiao CY, Ma H, Karibe H, Iwashima Y, Fukuzawa J, Hasebe N, Kikuchi K, Narumiya S, Ushikubi F. Effects of the prostanoids on the proliferation or hypertrophy of cultured murine aortic smooth muscle cells. Br J Pharmacol. 2002;36:530-539. Galis ZS. Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation. 2000;102:2861-2866 Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, Ivan E. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 2002;91:852-859. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res. 2004;61:498-511. Godin D, Ivan E, Johnson C, Magid R, Galis ZS. Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation. 2000;102:2861-2866 Guth BD, Narjes H, Schubert HD, Tanswell P, Riedel A, Nehmiz G. Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects. Br J Clin Pharmacol. 2004;58:40-51. Halushka PV, Mais DE, Saussy DL. Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors. Fed Proc. 1987;46:149-153. Hirata M, Hayashi Y, Ushikubi F Yokota Y, Kageyama R, Nakanishi S, Narumiya S. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature. 1991;349:617-620. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, and Herschman HR.TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991; 266:12866-12872. Lages B, Malmsten C, Weiss HJ. Impaired platelet response to thromboxane-A2 and defective calcium mobilization in a patient with a bleeding disorder. Blood. 1981;57:545-552. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med. 1994;330:981–993. Landry DW and Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588-595. Liu YN, Pan SL, Peng CY, Guh JH., Huang DM., Chang YL, Lin CH, Pai HC, Kuo Lee SC, FY, and Teng CM. YC-1[3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl Indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. J Pharmacol Exp Ther. 2006;316:35-41. Leung KH and Mihich E. Prostaglandin modulation of development of cell-mediated immunity in culture. Nature. 1980;288: 597-600. Lin ZH, Fukuda N, Suzuki R. Adenovirus-encoded hammerhead ribozyme to PDGF A-chain mRNA inhibits neointima formation after arterial injury. J Vasc Res. 2004;41:305-313 Massberg S, Vogt F, Dickfeld T, Brand K, Page S, Gawaz M. Activated platelets trigger an inflammatory response and enhance migration of aortic smooth muscle cells. Thromb Res. 2003;110:187-194. Mene P, Dunn MJ. Contractile effects of TXA2 and endoperoxide analogues on cultured rat glomerular mesangial cells. Am J Physiol. 1986;251:F1029-F1035. Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B. Identification of an enzyme in platelet microsomes which generates TXA2 from prostaglandin endoperoxides. Nature. 1976;261:558-560 Ogletree ML. Overview of physiological and pathophysiological effects of thromboxane A2. Fed Proc. 1987;46:133-138. Olson RW, Dotson R, Mathis J et al. Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis. Eur J Pharmacol. 1993;236:75-87. Pakala R. Serotonin and thromboxane A2 stimulate platelet-derived microparticle-induced smooth muscle cell proliferation. Cardiovasc Radiat Med. 2004 ;5:20-26. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993;328:1471-1477. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C, Weksler BB. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb Vasc Biol. 1994;14:1021–1031 Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood. 1994;83:885-898 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809. Samama M, Lecrubier C, Conard J et al. Constitutional thrombocytopathy with subnormal response to thromboxane A2. Br J Pharmacol. 1981;48:293-303. Sata M, Maejima Y, Adachi F, Fukino K, Saiura A, Sugiura S, Aoyagi T, Imai Y, Kurihara H, Kimura K, Omata M, Makuuchi M, Hirata Y, Nagai R. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol. 2000;32:2097–2104. Schini-Kerth VB, Bassus S, Fisslthaler B, Kirchmaier CM, Busse R. Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB. Circulation. 1997;96:3888-3896. Schwartz RS, Holmes Jr DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;20:1284-1293 Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med 1999;106:37S-42S. Sinzinger H, O'Grady J, Demers LM, Granstrom E, Kumlin M, Nell A, Peskar BA, Salmon JA, Westlund P. Thromboxane in cardiovascular disease. Eicosanoids. 1990;3:59-64. Smith WL, Marnett LJ, and DeWitt DL . Prostaglandin and thromboxane biosynthesis. Pharmacol Ther. 1991;49:153-179. Van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation.1994;89:36-44. Vane JR. The release and fate of vaso-active hormones in the circulation. Br J Pharmacol. 1969;35:209-242. Vezza R, Mezzasoma AM, Venditti G, Gresele P. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Thromb Haemost. 2002;87: 114-121. Viles-Gonzalez JF, Fuster V, Corti R, Valdiviezo C, Hutter R, Corda S, Anand SX, Badimon JJ. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study. Eur Heart J. 2005;26:1557-61. Wang H, Liu C, Song Y, Gordon D, Alavi MZ, Moore S. Expression of metalloproteinases and its inhibitor in later stage of rabbit neointima development. Int J Mol Med. 2001;7:105-112 Winn VD, O'Banion MK, and Young DA. Anti-inflammatory glucocorticoid action: inhibition of griPGHS, a new cyclooxygenase. J Lipid Mediat. 1993;6:101-111. Wu YJ, Hong CY, Lin SJ, Wu P, and Shiao MS. Increase of vitamin E content in LDL and reduction of atherosclerosis in cholesterol-fed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza. Arterioscler Thromb Vasc Biol. 1998 ;18:481-486. Yamada M, Numaguchi Y, Okumra K, Harada M, Narase K, Matsui H, Hayakawa T. Prostacyclin synthase gene transfer modulates cyclooxygenase-2-derived prostanoid synthesis and inhibits neointimal formation in rat balloon-injured arteries. Arterioscler Thromb Vasc Bio. 2002;22:256-262 Yu IS, Lin SR, Huang CC, Tseng HY, Huang PH, Shi GY, Wu HL, Tang CL, Chu PH, Wang LH, Wu KK, Lin SW. TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death. Blood. 2004;104:135-142. Zembowicz A, Jones SL, and Wu KK. Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine. J Clin Investig 1995;96: 1688–1692. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25735 | - |
dc.description.abstract | 引發血管再狹窄的主要原因之一是由於血管受傷,使血管壁內皮損傷,平滑肌細胞直接暴露於流動的血液,刺激血小板的大量活化與聚集,釋放及分泌促發炎因子造成血管的發炎反應並且形成血栓,使得位在中層的平滑肌細胞增生和移行,造成內膜增生。而在血小板的活化過程中,血栓素扮演了重要的角色。本篇論文當中,利用血栓素合成酶缺陷小鼠,探討股動脈擴張手術對其血管再狹窄的影響以及當中的機制。研究顯示:在動物模式中,經過股動脈擴張手術之後,野生型小鼠 (C57BL/6) 的血管之新生內膜相當厚 (內膜/中膜之比率:2.6±0.4),而血栓素合成酶缺陷小鼠的內膜增生情形相對的大幅度減少 (1.1±0.1)。以免疫組織染色法以及西方點墨法觀察,發現血栓素合成酶缺陷小鼠的新生內膜之COX-2與MMP-9表現相較於野生型小鼠也是減少的情形。在細胞模式中,將主動脈平滑肌細胞自野生型小鼠體內分離出來,以野生型和血栓素合成酶缺陷小鼠之活化的血小板刺激細胞,觀察其COX-2的表現。結果以野生型小鼠之活化的血小板刺激之下,平滑肌細胞的COX-2表現大量上升,而血栓素合成酶缺陷小鼠之活化的血小板刺激細胞之後,其COX-2表現相對減少。自上述實驗結果得知,血栓素合成酶缺陷的情形下,造成血栓素的缺乏,降低內膜增生和血管的發炎反應,表示抑制血栓素的形成能有效治療血管再狹窄。 | zh_TW |
dc.description.abstract | Platelets activation and aggregation are important factors in restenosis. Thromboxane A2 (TXA2) plays a major role in homeostasis, thrombosis, vasoconstriction, and vascular cell proliferation. Thromboxane A2 synthase (TXAS) is the key enzyme in TXA2 biosynthesis. The previous study has demonstrated that TXAS deletion protects mice against arachidonate-induced shock and death. To investigate the effects of TXA2 on neointimal hyperplasia and cyclooxygenase-2 (COX-2, an inflammatory cytokine), we used TXAS–/– mice as an animal model. A wire injury of the right femoral artery was performed when the age of mice was 5 months. Right and left femoral arteries of wild type and TXAS–/– mice were harvested at the end of 4 weeks of the injury. The neointimal hyperplasia in right femoral artery was significantly inhibited in TXAS–/–mice. The area ratios of the neointima to the media in the right femoral artery of TXAS–/–mice (intima/media ratio: 1.1±0.1) were significantly less when compared to that of wild type (2.6±0.4). The intima of left femoral arteries in TXAS–/– mice and wild type showed very thin. Weaker COX-2 and MMP-9 expressions were seen in the neointimal area of TXAS–/–mice. The thickened intima was composed of smooth muscle cells mainly. In cell culture model, isolated aortic smooth muscle cells from wild type mice was treated with thrombin-activated platelets supernatant from wild type and TXAS–/–mice. These results showed that COX-2 expression of smooth muscle cells was highly induced under the treatment of activated platelets from wide type mice. In contrast, COX-2 expression was attenuated in smooth muscle cells under the treatment of activated platelets from TXAS-/- mice. Base on these studies, we conclude that TXA2 may offer some effects on post-angioplasty restenosis and the inhibitory effects on intimal response after wire injury might be attributed to the deficiency of TXA2 | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T06:27:19Z (GMT). No. of bitstreams: 1 ntu-95-R93446007-1.pdf: 3897292 bytes, checksum: 410ba7428730c4eaaf4bc9c2ef7c2a35 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 目錄
中文摘要-----------------------------------------------------------------------------3 英文摘要-----------------------------------------------------------------------------5 縮寫表--------------------------------------------------------------------------------7 第一章、緒論-----------------------------------------------------------------------10 第二章、材料與方法-------------------------------------------------------------21 第三章、實驗結果----------------------------------------------------------------48 第四章、討論與結論-------------------------------------------------------------58 附圖----------------------------------------------------------------------------------65 參考文獻----------------------------------------------------------------------------81 附錄----------------------------------------------------------------------------------91 | |
dc.language.iso | zh-TW | |
dc.title | 血栓素合成酶缺陷對於動脈內膜增生的影響及其相關機制 | zh_TW |
dc.title | The effects of thromboxane A2 synthase deficiency on neointimal hyperplasia and the related mechanism | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 王淑美,林淑華,王寧,吳華林 | |
dc.subject.keyword | 內膜增生,血小板,平滑肌細胞,血栓素,環氧化酶,基質金屬酶, | zh_TW |
dc.subject.keyword | neointima hyperplasia,platelet,smooth muscle cell,thromboxane A2,cyclooxygenase-2,matrix metalloprotease-9, | en |
dc.relation.page | 95 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2006-07-27 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 解剖學研究所 | zh_TW |
顯示於系所單位: | 解剖學暨細胞生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 3.81 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。